Market Research Logo

Global Dna Vaccine Market Forecast 2018-2026

Global Dna Vaccine Market Forecast 2018-2026

KEY FINDINGS

The Global DNA vaccines market is predicted to grow at a CAGR of 41.89%, generating $xx million by the end of the forecast period of 2018-2026. Factors like increasing investments for third-generation vaccines, increasing adoption in animal healthcare and potential application of these vaccines in identifying growing prevalence of diseases is influencing the market growth.

MARKET INSIGHTS

The Global DNA Vaccines Market is segmented on the basis of types, technologies, and applications. The types are further segmented into animal DNA vaccine and human DNA vaccine. The market technologies include plasmid DNA vaccines and Plasmid DNA delivery. The market finds its applications for veterinary as well as human diseases. At present, veterinary applications are leading the segment.

REGIONAL INSIGHTS

The Global DNA vaccines market covers the regions of North America, Asia-Pacific, Europe and rest of world. The North American market is expected to hold a dominant share by the end of the forecast period. The rising prevalence of incessant diseases in countries such as the US and Canada is fueling the market growth. The Asia-Pacific region is expected exhibit the fastest growth between 2018-2026, due to emerging interests in third-generation DNA vaccination, government support, and increasing conduction of clinical trials.

COMPETITIVE INSIGHTS

Eurogentec S.A, Madison Vaccines Incorporated (MVI), Sanofi, Inovio Pharmaceuticals Inc and Novartis Ag are the leading market players in the global market. The other key market companies include Astellas Pharma Inc, Dendreon Corporation, Eli Lilly And Company, Glaxosmithkline Inc, Merial Limited (Acquired By Boehringer Ingelheim), Merck & Co, Vgxi, Vical Incorporated, Xenetic Biosciences Inc and Zoetis Inc.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Active Clinical Trials For Human Dna Vaccine Is Fueling The Market Growing Potential
3.2.2. North America Is The Global Leader In Dna Vaccine Market
3.2.3. Veterinary Diseases Leads The Application Segment Of The Dna Vaccine Market
3.2.4. Cancer Treatment Are An Important Focus For Dna Vaccine Clinical Trials
4. Market Determinants
4.1. Drivers
4.1.1. Dna Vaccines Shows Great Promise In Checking Rising Prevalence Of Disease
4.1.2. Third Generation Vaccination Is Seeing A Surge Of Investment
4.1.3. Increasing Adoption Of Dna Vaccines For Animal Healthcare
4.2. Restraints
4.2.1. Lengthy Regulatory Process
4.2.2. Poor Patent Protection In Some Countries
4.3. Opportunities
4.3.1. Transforming Healthcare Landscape
4.3.2. New Developments In Biotechnologies And Nanotechnologies
4.3.3. Stable Vaccines Make It Attractive To Store And Transport
4.4. Challenges
4.4.1. Vaccines For Human Usage Still Under Clinic Trail Phase
5. Market Segmentation
5.1. Market By Type 2018-2026
5.1.1. Animal Dna Vaccine
5.1.2. Human Dna Vaccine
5.2. Market By Application 2018-2026
5.2.1. Human Disease
5.2.2. Veterinary Disease
5.3. Market By Technology 2018-2026
5.3.1. Plasmid Dna Vaccines
5.3.2. Plasmid Dna Delivery
6. Key Analytics
6.1. Porter’s Five Force Model
6.1.1. Threat Of New Entrants
6.1.2. Threats Of Substitute Product
6.1.3. Bargaining Power Of Buyer
6.1.4. Bargaining Power Of Supplier
6.1.5. Intensity Of Competitive Rivalry
6.2. Key Buying Criteria
6.2.1. Efficacy
6.2.2. Cost-effectiveness
6.2.3. Stability
6.3. Key Market Players
6.3.1. Vical Incorporated
6.3.2. Sanofi
6.3.3. Merck And Corp
6.3.4. Gsk
6.4. Opportunity Matrix
6.5. Value Chain Analysis
6.5.1. R&D
6.5.2. Manufacturing
6.5.3. Raw Materials
6.5.4. Marketing, Distribution & End User
6.6. Legal, Policy And Regulatory Framework
7. Geographical Analysis
7.1. North America
7.1.1. United States
7.1.2. Canada
7.2. Europe
7.2.1. United Kingdom
7.2.2. France
7.2.3. Germany
7.2.4. Spain
7.2.5. Rest Of Europe
7.3. Asia Pacific
7.3.1. India
7.3.2. China
7.3.3. Japan
7.3.4. Australia
7.3.5. Rest Of Asia Pacific
7.4. Rest Of The World
7.4.1. Latin America
7.4.2. Middle East & Africa
8. Competitive Landscape
8.1. Strategic Initiatives
8.1.1. Acquisition
8.1.2. Partnership
8.1.3. Collaboration
8.1.4. Innovation
8.1.5. Disinvestment
8.1.6. Expansion
9. Company Profile
9.1. Market Share
9.2. Astellas Pharma Inc.
9.2.1. Overview
9.2.2. Product Portfolio
9.2.3. Scot Analysis
9.2.4. Strategic Initiative
9.3. Dendreon Corporation (Acquired By Sanpower Group)
9.3.1. Overview
9.3.2. Product Portfolio
9.3.3. Scot Analysis
9.3.4. Strategic Initiative
9.4. Eli Lilly And Company
9.4.1. Overview
9.4.2. Product Portfolio
9.4.3. Scot Analysis
9.4.4. Strategic Initiative
9.5. Eurogentec S.A
9.5.1. Overview
9.5.2. Product Portfolio
9.5.3. Scot Analysis
9.5.4. Strategic Initiative
9.6. Glaxosmithkline Inc.
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Scot Analysis
9.6.4. Strategic Initiatives
9.7. Inovio Pharmaceuticals, Inc.
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Scot Analysis
9.7.4. Strategic Initiative
9.8. Madison Vaccines Incorporated (Mvi)
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Scot Analysis
9.9. Merial Limited (Acquired By Boehringer Ingelheim)
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Scot Analysis
9.9.4. Strategic Initiative
9.10. Merck & Co.
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Scot Analysis
9.10.4. Strategic Initiative
9.11. Novartis Ag
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Scot Analysis
9.11.4. Strategic Initiative
9.12. Sanofi
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Scot Analysis
9.12.4. Strategic Initiative
9.13. Vgxi
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Scot Analysis
9.13.4. Strategic Initiatives
9.14. Vical Incorporated
9.14.1. Overview
9.14.2. Product Portfolio
9.14.3. Scot Analysis
9.14.4. Strategic Initiative
9.15. Xenetic Biosciences Inc.
9.15.1. Overview
9.15.2. Product Portfolio
9.15.3. Scot Analysis
9.15.4. Strategic Initiates
9.16. Zoetis Inc
9.16.1. Overview
9.16.2. Product Portfolio
9.16.3. Scot Analysis
9.16.4. Strategic Initiates
Table List
Table 1 Global Dna Vaccine Market By Geographies 2018-2026 ($ Million)
Table 2 Interventions And Phase Of Certain Disease/Conditions
Table 3 Approaches Being Tested To Enhance The Low Immunogenicity
Table 4 Clinical Trials Of The Humans Involving Dna Vaccines
Table 5 Temperature Requirements In Preservation For Various Vaccines
Table 6 Global Dna Vaccine Market By Type 2018-2026 ($ Million)
Table 7 Global Dna Vaccine Market In Animal Dna Vaccine By Geography 2018-2026($million)
Table 8 Global Dna Vaccine Market In Human Dna Vaccine By Geography 2018-2026
Table 9 Global Dna Vaccine Market By Application 2018-2026 ($ Million)
Table 10 Global Dna Vaccine Market In Human Diseases Application By Geography 2018-2026 ($million)
Table 11 Global Dna Vaccine Market In Veterinary Application By Geography 2018-2026
Table 12 Global Dna Vaccine Market By Technology 2018-2026 ($ Million)
Table 13 Global Dna Vaccine Market In Plasmid Dna Vaccines Technology By Geography 2018-2026
Table 14 Global Dna Vaccine Market In Plasmid Dna Delivery Technology By Geography 2018-2026
Table 15 Regulations To Be Followed Before Commercialization
Table 16 Global Dna Vaccines Market, By Geographies 2018-2026 ($ Million)
Table 17 North America Dna Vaccine Market 2018-2026 ($ Million)
Table 18 Europe Dna Vaccine Market 2018-2026 ($ Million)
Table 19 Asia Pacific Dna Vaccines Market 2018-2026 ($ Million)
Table 20 Rest Of The World Dna Vaccines Market 2018-2026 ($ Million)
Figures List
Figure 1 Global Dna Vaccine Market 2018-2026 ($ Million)
Figure 2 North America Dna Vaccine Market 2018-2026 ($ Million)
Figure 3 Global Dna Vaccine Market In Veterinary Diseases 2018-2026 ($ Million)
Figure 4 Share Of Trials By Vaccine Target In 2016
Figure 5 Segment Of Clinical Trials Of Dna Vaccine By Cancer Marks In 2016
Figure 6 Clinical Trials Of Gene Theraphy
Figure 7 Global Dna Vaccine Market Share By Type 2017 & 2026 (%)
Figure 8 Global Dna Vaccines Market In Animal Dna Vaccines 2018-2026 ($ Million)
Figure 9 Global Dna Vaccine Market In Human Dna Vaccines 2018-2026($ Million)
Figure 10 Global Dna Vaccine Market Share By Application 2017 & 2026 (%)
Figure 11 Global Dna Vaccines Market In Human Diseases 2018-2026 ($ Million)
Figure 12 Global Dna Vaccines Market In Vterinary Application 2018-2026 ($ Million)
Figure 13 Global Dna Vaccines Market In Plasmid Dna Vaccines Technology 2018-2026 ($ Million)
Figure 14 Global Dna Vaccines Market In Plasmid Dna Delivery Technology 2018-2026 ($ Million)
Figure 15 Value Chain Analyses For Dna Vaccine Industry
Figure 16 United States Dna Vaccine Market 2018-2026 ($ Million)
Figure 17 Canada Dna Vaccine Market 2018-2026 ($ Million)
Figure 18 United Kingdom Dna Vaccine Market 2018-2026 ($ Million)
Figure 19 France Dna Vaccine Market 2018-2026 ($ Million)
Figure 20 Germany Dna Vaccine Market 2018-2026 ($ Million)
Figure 21 Spain Dna Vaccine Market 2018-2026 ($ Million)
Figure 22 Rest Of Europe Dna Vaccine Market 2018-2026 ($ Million)
Figure 23 India Dna Vaccine Market 2018-2026 ($ Million)
Figure 24 China Dna Vaccine Market 2018-2026 ($ Million)
Figure 25 Japan Dna Vaccine Market 2018-2026 ($ Million)
Figure 26 Australia Dna Vaccine Market 2018-2026 ($ Million)
Figure 27 Rest Of Asia Pacific Dna Vaccine Market 2018-2026 ($ Million)
Figure 28 Latin America Dna Vaccine Market 2018-2026 ($ Million)
Figure 29 Mena Dna Vaccine Market 2018-2026 ($ Million)
Figure 30 Market Shares Of Top Five Companies For Dna Vaccines Market In 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report